TrialViruses2022
DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).
Carmen Hidalgo-Tenorio et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
13 papers cite it
this paperpooled itcites it
TrialViruses2022
Carmen Hidalgo-Tenorio et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.